ZACKS INVESTMENT MANAGEMENT - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 93 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.6%.

Quarter-by-quarter ownership
ZACKS INVESTMENT MANAGEMENT ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q4 2020$1,054,000
-22.7%
150,542
-9.9%
0.02%
-32.1%
Q3 2020$1,363,000
-26.6%
167,088
-37.9%
0.03%
-31.7%
Q2 2020$1,856,000
+7.7%
268,981
-25.8%
0.04%
-2.4%
Q1 2020$1,723,000
+54.4%
362,639
+183.7%
0.04%
+100.0%
Q4 2019$1,116,000127,8360.02%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q2 2020
NameSharesValueWeighting ↓
TRV GP II, LLC 10,230,349$63,428,00041.36%
TRV GP III, LLC 3,048,780$18,902,0009.26%
Omega Fund Management, LLC 1,059,930$6,572,0001.39%
Alambic Investment Management, L.P. 50,622$314,0000.13%
Spark Investment Management LLC 244,300$1,514,0000.07%
ALGERT GLOBAL LLC 14,182$88,0000.05%
Redmile Group, LLC 254,590$1,578,0000.05%
Granahan Investment Management 125,533$778,0000.04%
GSA CAPITAL PARTNERS LLP 38,602$239,0000.02%
Frontier Wealth Management LLC 27,099$168,0000.02%
View complete list of JOUNCE THERAPEUTICS INC shareholders